207_Combined course Presentations

Feasibility of ”reduced dose” WBRT

 Chemotherapy schedule R-MVP x 5-7 cycles • Rituximab • Methotrexate • Vincristine • Procarbazine

Outcomes of patients receiving rdWBRT

 WBRT •

rdWBRT (23.4 Gy/13 fr) in patients who achieved CR • Standard WBI (45 Gy/25 fr) in patients with PR-SD-PD

 Consolidative CT •

High dose ARA-Cx 2 cycles

Median OS not reached Median OS 7.7 years

CR rate: 47% ORR rate: 95%

Morris PG et. al JCO 2013;31